MIM
ITCI

Monashee Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Monashee Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Hold
0
– – – 33
2015
Q2 		– Sell
-63,978
Closed -$1.53M – 97
2015
Q1 		$1.53M Buy
+63,978
New +$1.43M 0.95% 36

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Monashee Investment Management's ITCI Position: Q3 2017 in Review

Monashee Investment Management held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q3 2017 at 0 shares worth $3.06M. The position accounts for 1.16% of the portfolio, ranked #33.

Monashee Investment Management first reported a position in ITCI in Q1 2015 and has held it in 1 quarter since. The position peaked at $1.53M in Q1 2015. 137 funds tracked by Wall St. Rank hold ITCI as of Q3 2017.

  • Monashee Investment Management held 0 shares of Intra-Cellular Therapies Inc. worth $3.06M as of Q3 2017.
  • Monashee Investment Management left its Intra-Cellular Therapies Inc. share count unchanged in Q3 2017.
  • Intra-Cellular Therapies Inc. made up 1.16% of Monashee Investment Management's portfolio in Q3 2017, its #33 holding.
  • Monashee Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and has held it in 1 quarter since.
  • Monashee Investment Management's Intra-Cellular Therapies Inc. position peaked at $1.53M in Q1 2015.
  • 137 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2017.

Based on Monashee Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.